CA2194221A1 - Amphiphiles cationiques - Google Patents

Amphiphiles cationiques

Info

Publication number
CA2194221A1
CA2194221A1 CA2194221A CA2194221A CA2194221A1 CA 2194221 A1 CA2194221 A1 CA 2194221A1 CA 2194221 A CA2194221 A CA 2194221A CA 2194221 A CA2194221 A CA 2194221A CA 2194221 A1 CA2194221 A1 CA 2194221A1
Authority
CA
Canada
Prior art keywords
cationic amphiphiles
amphiphiles
cationic
diacylphosphatidyl
intracellularly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2194221A
Other languages
English (en)
Other versions
CA2194221C (fr
Inventor
Timothy D. Heath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urigen Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2194221A1 publication Critical patent/CA2194221A1/fr
Application granted granted Critical
Publication of CA2194221C publication Critical patent/CA2194221C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA002194221A 1994-06-22 1994-06-22 Amphiphiles cationiques Expired - Fee Related CA2194221C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/007071 WO1995035301A1 (fr) 1994-06-22 1994-06-22 Amphiphiles cationiques

Publications (2)

Publication Number Publication Date
CA2194221A1 true CA2194221A1 (fr) 1995-12-28
CA2194221C CA2194221C (fr) 2001-01-02

Family

ID=22242692

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002194221A Expired - Fee Related CA2194221C (fr) 1994-06-22 1994-06-22 Amphiphiles cationiques

Country Status (6)

Country Link
EP (1) EP0807116A4 (fr)
JP (1) JPH10506093A (fr)
AU (1) AU696881B2 (fr)
CA (1) CA2194221C (fr)
NO (1) NO970172D0 (fr)
WO (1) WO1995035301A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5976567A (en) * 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6235310B1 (en) 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
JP4799736B2 (ja) 1999-02-22 2011-10-26 ジョージタウン・ユニバーシティ 全身性遺伝子送達のための抗体フラグメント標的化イムノリポソーム
US9034329B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
US9034330B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
AU2002307035A1 (en) * 2001-04-02 2002-10-15 Georgetown University A simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome or polyplex for systemic administration of a therapeutic or diagnostic agent
DE10207178A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
EP1519714B1 (fr) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Appareil liposomal et procedes de fabrication
CA2532228C (fr) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Arn interferant encapsule dans un lipide
EP1664316B1 (fr) 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Composes lipidiques modifies avec du polyethyleneglycol et utilisations de ces composes
JP4764426B2 (ja) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
CA2569664C (fr) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Arn interferant encapsule dans des lipides
EP1773857A4 (fr) 2004-07-02 2009-05-13 Protiva Biotherapeutics Inc Molecules sirna immunostimulatrices et utilisations de celles-ci
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
CA2721333C (fr) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Nouvelles formulations lipidiques pour l'administration d'acides nucleiques
CA2740000C (fr) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Lipides amines ameliores et procedes d'administration d'acides nucleiques
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011000107A1 (fr) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Formulations lipidiques inédites permettant l'administration d'agents thérapeutiques en direction de tumeurs solides
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
CA2916898A1 (fr) 2013-07-16 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Amelioration du potentiel osteogenique des greffons osseux
WO2022115645A1 (fr) 2020-11-25 2022-06-02 Akagera Medicines, Inc. Nanoparticules lipidiques utilisées pour l'administration d'acides nucléiques, et méthodes d'utilisation associées
CA3256897A1 (fr) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Nanoparticules lipidiques pour l'administration d'acides nucléiques et leurs procédés d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3239817A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue glycerinderivate zur synthese von phospholipiden
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection

Also Published As

Publication number Publication date
AU696881B2 (en) 1998-09-24
NO970172L (no) 1997-01-15
WO1995035301A1 (fr) 1995-12-28
EP0807116A4 (fr) 1998-01-07
EP0807116A1 (fr) 1997-11-19
CA2194221C (fr) 2001-01-02
JPH10506093A (ja) 1998-06-16
NO970172D0 (no) 1997-01-15
AU7471194A (en) 1996-01-15

Similar Documents

Publication Publication Date Title
CA2194221A1 (fr) Amphiphiles cationiques
EP0601618A3 (en) Use of charged phospholipids for decreasing nanoparticulate aggregation.
AU2192395A (en) Novel cationic phospholipids for transfection
CA2133175A1 (fr) Compositions de rapamycine pour administration orale
AU5127193A (en) Methods for the synthesis of phosphonate esters
AU3955089A (en) Pharmaceutical composition comprising protein kinase c inhibitor and anti-cancer agent
AU3575193A (en) S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
WO2000061543A3 (fr) Esters de l-carnitine ou de l-carnitines alcanoyles utilises comme lipides cationiques pour un apport intracellulaire de composes actifs d'un point de vue pharmacologique
WO1987000752A3 (fr) Composes bicycliques amphoteriques et leurs sels, solvats, hydrates et esters
TW255880B (fr)
AU2616895A (en) Hybrid molecule of formula gm-csf-l-epo or epo-l-gm-csf for hematopoietic stimulation
GR3025368T3 (en) Non active substance containing liposomes for the treatment of atherosclerosis
BG103260A (en) The application of 1-hydroxy-2-pyridons for the treatment of seborrheic dermatitis
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye
AU6581294A (en) Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
IT1238300B (it) Apparecchiatura per l'immagazzinamento temporaneo di prodotti.
ITMI930101A0 (it) Procedimeno per l'impacchettamento di prodotti freschi
AU644002B2 (en) Polysulfide compounds and lipid peroxidation inhibitor containing the polysulfide compounds as active ingredient
AU3344795A (en) Transferrin compositions to alleviate the side effects of cytotoxic drugs
AU647296B2 (en) Procedure for the producing of vanadium bis-arenes from vanadium oxychloride
AU3725895A (en) Administration of a 27-hydroxycholesterol or prodrug thereof as an anti-cancer agent
AU3542697A (en) Pharmaceutical formulations for topical application containing as an active ingredient carbazolyl-(4)-oxy-propanol amine derivate
AU4182693A (en) Isothiazole derivatives and processes for preparing the same as well as termite controlling agents comprising the same as active ingredient
AU5533694A (en) Lipid level depressant containing penicillide compound as active ingredient
CA2261706A1 (fr) Utilisation de composes modulateurs du facteur de croissance

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed